Transition of DNA-HPV over time in HPV-infected women: a 7-year cohort study
DOI:
https://doi.org/10.13181/mji.oa.247340Keywords:
DNA, HPV infection, Vietnam, womenAbstract
BACKGROUND Approximately 99% of cervical cancer cases worldwide are associated with one of the high-risk human papillomavirus (HPV) types. This study aimed to determine the transition rate of DNA-HPV over time in women aged 18–69 years with HPV infection in Can Tho City, Vietnam, from 2013 to 2020.
METHODS The 2-phase cohort study was conducted on 213 women between 2013 and 2020. Phase 1 involved a retrospective cohort study (2013–2018), and phase 2 included a prospective cohort study (2018–2020). HPV testing was performed using real-time polymerase chain reaction on cervical fluid. McNemar’s test was employed to compare differences in HPV transition between 2013 and 2020.
RESULTS From 2013 to 2018, the transition, clearance, and non-transition rates were 17.1%, 65.8%, and 66.2%, respectively, revealing a significant difference in the number of HPV cases during this period (p = 0.007). From 2018 to 2020, the transition, clearance, and non-transition rates were 9.8%, 44.9%, and 82.2%, respectively. Overall, the DNA-HPV changes from 2013 to 2020 indicated rates of 14.3% for transition, 68.5% for clearance, and 67.1% for non-transition. A significant difference in HPV cases was found between 2013 and 2020 (p = 0.001).
CONCLUSIONS The longer duration resulted in a more significant difference in the DNA-HPV transition among HPV-infected women.
Downloads
References
Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases report. Summary Report 10 March 2023. ICO/IARC Information Centre on HPV and Cancer, HPV Information Centre; 2019.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. https://doi.org/10.3322/caac.21332
Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases report, Viet Nam. Summary Report 10 March 2023. ICO/IARC Information Centre on HPV and Cancer, HPV Information Centre; 2019.
Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol. 2015;125(2):330-7. https://doi.org/10.1097/AOG.0000000000000669
Katanga J, Kjaer SK, Manongi R, Wu CS, Iftner T, Waldstrom M, et al. Performance of careHPV, hybrid capture 2 and visual inspection with acetic acid for detection of high-grade cervical lesion in Tanzania: a cross-sectional study. PLoS One. 2019;14(6):e0218559. https://doi.org/10.1371/journal.pone.0218559
Seo SS, Oh HY, Kim MK, Lee DO, Chung YK, Kim JY, et al. Combined effect of secondhand smoking and alcohol drinking on risk of persistent human papillomavirus infection. Biomed Res Int. 2019;2019:5829676. https://doi.org/10.1155/2019/5829676
de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324(1):17-27. https://doi.org/10.1016/j.virol.2004.03.033
Howley PM, Schiller JT, Lowy DR. Papillomaviruses. In: Knipe DM, Howley PM, editors. Fiel virology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 1662-703.
Hogewoning CJ, Bleeker MC, van den Brule AJ, Voorhorst FJ, Snijders PJ, Berkhof J, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer. 2003;107(5):811-6. https://doi.org/10.1002/ijc.11474
Bardin A, Vaccarella S, Clifford GM, Lissowska J, Rekosz M, Bobkiewicz P, et al. Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland. Eur J Cancer. 2008;44(4):557-64. https://doi.org/10.1016/j.ejca.2007.12.001
Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789-99. https://doi.org/10.1086/657321
Berek JS. Berek & Novak's gynecology. 16th ed. Philadelphia: Lippincott Williams & Wilkins; 2019.
Xia C, Li S, Long T, Chen Z, Chan PKS, Boon SS. Current updates on cancer-causing types of human papillomaviruses (HPVs) in East, Southeast, and South Asia. Cancers (Basel). 2021;13(11):2691. https://doi.org/10.3390/cancers13112691
Villa LL. Chapter 1 biology of genital human papillomaviruses. Int J Gynaecol Obstet. 2006;94 Suppl 1:S3-7. https://doi.org/10.1016/S0020-7292(07)60003-4
World Health Organization (WHO). Cervical cancer [Internet]. World Health Organization (WHO); 2022 [cited 2023 May 5]. Available from: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer#:~:text.
Robles C, Hernández ML, Almonte M. Alternative HPV vaccination schedules in Latin America. Salud Publica Mex. 2018;60(6):693-702. https://doi.org/10.21149/9810
Umulisa MC, Franceschi S, Baussano I, Tenet V, Uwimbabazi M, Rugwizangoga B, et al. Evaluation of human-papillomavirus testing and visual inspection for cervical cancer screening in Rwanda. BMC Womens Health. 2018;18(1):59. https://doi.org/10.1186/s12905-018-0549-5
Li M, Liu T, Luo G, Sun X, Hu G, Lu Y, et al. Incidence, persistence and clearance of cervical human papillomavirus among women in Guangdong, China 2007-2018: a retrospective cohort study. J Infect Public Health. 2021;14(1):42-9. https://doi.org/10.1016/j.jiph.2020.11.011
Gravitt PE. The known unknowns of HPV natural history. J Clin Invest. 2011;121(12):4593-9. https://doi.org/10.1172/JCI57149
Shanmugasundaram S, You J. Targeting persistent human papillomavirus infection. Viruses. 2017;9(8):229. https://doi.org/10.3390/v9080229
Jensen KE, Schmiedel S, Norrild B, Frederiksen K, Iftner T, Kjaer SK. Parity as a cofactor for high-grade cervical disease among women with persistent human papillomavirus infection: a 13-year follow-up. Br J Cancer. 2013;108(1):234-9. https://doi.org/10.1038/bjc.2012.513
Koshiol JE, Schroeder JC, Jamieson DJ, Marshall SW, Duerr A, Heilig CM, et al. Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer. 2006;119(7):1623-9. https://doi.org/10.1002/ijc.22015
Nogara PR, Manfroni LA, Consolaro ME. Frequency of cervical intraepithelial neoplasia grade II or worse in women with a persistent low-grade squamous intraepithelial lesion seen by Papanicolaou smears. Arch Gynecol Obstet. 2013;288(5):1125-30. https://doi.org/10.1007/s00404-013-2872-2
Duong LM, Pham LV, Pham TT, Tran DN, Bui NQ, Tran HD, et al. DNA-HPV transition rate and related factors in HPV-infected women in Can Tho city, Vietnam. Trop Med Int Health. 2019;24(11):1330-4. https://doi.org/10.1111/tmi.13309
Ek WE, Johansson T, Höglund J, Rask-Andersen M, Karlsson T, Johansson A. Long-term health related risks and benefits of oral contraceptive use. Lancet. 2019:1-28. https://doi.org/10.2139/ssrn.3384895
Kabir A, Bukar M, Nggada HA, Rann HB, Gidado A, Musa AB. Prevalence of human papillomavirus genotypes in cervical cancer in Maiduguri, Nigeria. Pan Afr Med J. 2019;33:284. https://doi.org/10.11604/pamj.2019.33.284.18338
Wu W, Song L, Yang Y, Wang J, Liu H, Zhang L. Exploring the dynamics and interplay of human papillomavirus and cervical tumorigenesis by integrating biological data into a mathematical model. BMC Bioinformatics. 2020;21(Suppl 7):152. https://doi.org/10.1186/s12859-020-3454-5
Orang'o EO, Were E, Rode O, Muthoka K, Byczkowski M, Sartor H, et al. Novel concepts in cervical cancer screening: a comparison of VIA, HPV DNA test and p16INK4a/Ki-67 dual stain cytology in Western Kenya. Infect Agent Cancer. 2020;15:57. https://doi.org/10.1186/s13027-020-00323-6
Published
How to Cite
Issue
Section
License
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.
